A Study to Evaluate the Efficacy and Safety of AD-208
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia
In the register
The register attaches this trial to AD-208 (low-dose dutasteride) (Addpharma), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Addpharma Inc.
- Participants (registry)
- 139
- Start
- June 2021
- Primary completion
- January 2023
- Study completion
- June 2023
- Last registry update
- July 2023
- Countries
- South Korea
Conditions studied: Androgenetic Alopecia
Interventions: AD-208, AD-2081, placebo of AD-208, placebo of AD-2081
Other trials of AD-208 (low-dose dutasteride)
To Evaluate the Pharmacokinetics and Safety of AD-208
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.